A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy

Inclusion Criteria:

1. Histologically or cytologically confirmed diagnosis of Differentiated Thyroid Cancer
(DTC)

2. Measurable disease according to RECIST 1.1

3. Previously treated with or deemed ineligible for treatment with Iodine- 131 for DTC

4. Previously treated with at least one of the following VEGFR-targeting TKI agents for
DTC: lenvatinib or sorafenib. Note: Up to two prior VEGFR-targeting TKI agents are
allowed

5. Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1

Exclusion Criteria:

1. Prior treatment with any of the following: Cabozantinib; Selective small-molecule BRAF
kinase inhibitor; More than 2 VEGFR-targeting TKI agents; More than 1 immune
checkpoint inhibitor therapy; 1 systemic chemotherapy regimen (given as single agent
or in combination with another chemotherapy agent)

2. Receipt of any type of small molecule kinase inhibitor (including investigational
kinase inhibitor) within 2 weeks or 5 half-lives of the agent, whichever is longer,
before randomization

3. Receipt of any type of anticancer antibody (including investigational antibody) or
systemic chemotherapy within 4 weeks before randomization

4. Receipt of radiation therapy for bone metastasis within 2 weeks or any other radiation
therapy within 4 weeks before randomization.

5. Known brain metastases or cranial epidural disease unless adequately treated